• Thursday, May 3, 8:23 PM PDL BioPharma (PDLI): Q1 EPS of $0.29 beats by $0.02. Revenue of $77.3M (-7.2% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
• Thursday, February 23, 5:36 PM Protein Design Labs (PDLI): Q4 EPS of $0.24 misses by $0.04. Revenue of $72.8M (-4.3% Y/Y) in-line. Shares -0.9% AH. (PR) Comment! [Earnings, Healthcare]
• Monday, December 19, 9:05 AM PDL BioPharma (PDLI) -3.5% premarket after issuing downward guidance for its Q4 and FY2012 revenue, citing reduced royalties from the sale of two drugs. PDL, which obtains most of its revenue from development and licensing of antibodies, generally has seen its bottom line improve in recent quarters amid lower expenses. Comment! [Healthcare, Earnings, On the Move]
• Tuesday, October 11, 12:42 PM PDL BioPharma (PDLI -4%) trades lower on an RBC downgrade to Sector Perform on valuation. Analyst Jason Kantor says the stock appears to have "topped out," adding the company is having trouble finding new sources of revenue. Comment! [Healthcare, On the Move]
• Thursday, September 8, 9:04 AM PDL BioPharma (PDLI) says it expects Q3 revenue of $83M (-3% Y/Y), guidance below analyst estimates of $87.7M. The firm expects reduced royalty revenue from Avastin to only be partially offset by an increase in royalties from Herceptin, Lucenits and Tysabi. Shares -1.2% premarket. Comment! [Healthcare, Earnings]
• Thursday, June 9, 7:33 AM PDL BioPharma (PDLI) revises its Q2 revenue guidance to ~$122M, down from prior guidance of $128M, due to a mathematical error made on the earlier guidance. Shares -1.5%. (PR) Comment! [Breaking News, Healthcare]
• Friday, August 13, 9:00 AM Premarket gainers: UNCA +118%. DYN +62%. ALY +61%. VECO +7%. NVDA +4%.
  Losers: PDLI -15%. DEG -9%. JWN -5%. LLY -4%. AIB -4%. Comment!
• Thursday, April 29, 4:08 PM Protein Design Labs (PDLI): Q1 EPS of $0.15 vs. consensus of $0.23. Revenue of $62.1M (-0.9%) vs. $72.3M. Shares -0.7% AH. (PR) Comment!
• Thursday, April 29, 12:10 AM Notable earnings after Thursday's close: AEM, AMCC, AMX, ANH, BEXP, BMRN, BVN, BYI, CTV, CYBS, ELY, EXPE, FISV, GNW, HGSI, HIG, IM, ITMN, KLAC, MET, MFE, MWW, MXIM, NETL, OCLR, PDLI, QLGC, RGC, RSG, SUN, SWKS, SWN, TSO, WFR, WYNN Comment!
• Tuesday, March 2, 4:07 PM PDL BioPharma (PDLI): Q4 EPS of $0.17 misses by $0.02. Revenue of $58.3M (-15%) vs. $70.3M. Shares +0.6% AH. (8-K) Comment!
• Tuesday, March 2, 12:10 AM Notable earnings after Tuesday's close: EGLE, HOV, PDLI Comment!
• Thursday, July 30, 4:44 PM PDL BioPharma (PDLI): Q2 EPS of $0.47 beats by $0.04. Revenue of $126M (+18%) vs. $124M. Sees full-year revenue of $310M-325M vs. $331M. Shares +1.6% AH. (PR) Comment!
• Thursday, July 30, 12:10 AM Notable earnings after Thursday's close: ARBA, ARIA, ARRS, BMRN, CPT, CYH, DIS, DRYS, DTE, ESLR, EXEL, FSLR, GERN, GNW, HLIT, HLTH, IM, LVS, MET, MHK, MWW, PBI, PDLI, PKI, SGY, SLW, SWN, SYNA, VPRT, VSEA, WRI, YRCW Comment!
• Thursday, May 7, 3:10 PM Notable earnings after Thursday's close: AGO, AIG, ALL, ATVI, BYI, CBS, CNQ, CROX, DCT, FCH, GNW, HANS, IPI, LEAP, MCHP, MRX, NHP, NVDA, PDLI, POM, PSA, RMD, SAPE, SD, SGMS, SHO, SVR, VRSN Comment!
• Thursday, May 7, 12:10 AM Notable earnings after Thursday's close: AGO, AIG, ALL, ATVI, BYI, CBS, CNQ, CROX, DCT, FCH, GNW, HANS, IPI, LEAP, MCHP, MRX, NHP, NVDA, PDLI, POM, PSA, RMD, SAPE, SD, SGMS, SHO, SVR, VRSN Comment!
• Monday, March 2, 3:10 PM Notable earnings after Monday's close: EGLE, FR, HPT, MDR, PDLI, POM, TIVO Comment!